Deep Discounts Continue
Prices slashed for first biotech IPOs of 2011: Pacira, Endocyte, BG Medicine
Deep discounts continue
The final U.S. IPOs in 2010 slashed their deal prices more than in half just before pricing. If the first few IPOs this year are any indication, that pattern will continue.
The first IPO out this year - specialty pain play Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) - cut its price to